8 assets in Central Nervous System Cancer

Therapeutic assets addressing Central Nervous System Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Rvp-001 Central Nervous System Cancer	Reveal Pharmaceuticals Inc.	P2	B (57)
Avapritinib Central Nervous System Cancer	M.D. Anderson Cancer Center	P2	CCC (53)
Cabozantinib Central Nervous System Cancer	National Cancer Institute (NCI)	P2	CCC (53)
TZ-3321 Central Nervous System Cancer	Washington University School of Medicine	P2	CCC (53)
Ulixertinib Central Nervous System Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Cbl-0137 Free Base Central Nervous System Cancer	Children's Oncology Group	P1/2	CC (44)
G 207 Central Nervous System Cancer	M.D. Anderson Cancer Center	P1	CC (43)
Onc 206 Central Nervous System Cancer	Sabine Mueller, MD, PhD	P1	CC (43)